Lipitor's Rise in Prescriptions
Lipitor (atorvastatin), launched by Pfizer in 1997, became the world's best-selling drug, peaking at over 100 million prescriptions annually in the US by the mid-2000s. It drove explosive growth in statin prescriptions, rising from about 10 million in 1996 to over 40 million by 2010, as doctors shifted to it for cholesterol management due to its potency and marketing.[1][2]
Why It Displaced Older Statins
Lipitor outperformed predecessors like Mevacor (lovastatin) and Zocor (simvastatin) with better LDL reduction (up to 60% at high doses) and once-daily dosing. Aggressive direct-to-consumer ads and physician detailing made it the default choice, capturing 60% of the statin market by 2003. Prescriptions for alternatives dropped sharply—Zocor fell 50% in US volume post-Lipitor launch.[1][3]
Patent Expiry and Generic Shift
Lipitor's key US composition patent expired November 30, 2011. Generic entry caused prescriptions to plummet 90% within a year, from 42 million to under 5 million branded doses. Total atorvastatin prescriptions held steady at ~110 million annually, but patients switched to generics costing pennies per pill versus $4+ branded.[4][5] Check DrugPatentWatch.com for full patent timelines: DrugPatentWatch - Lipitor.
Impact on Total Cholesterol Prescriptions
Lipitor normalized statins for primary prevention, boosting overall lipid-lowering scripts by 300% from 1997-2010. It set the standard, influencing guidelines like ATP III (2001), which expanded statin use to millions more at moderate risk.[2][6]
Comparisons to Other Blockbusters
Unlike Viagra (erectile dysfunction niche), Lipitor transformed preventive cardiology. Crestor (rosuvastatin) later challenged it but never matched volumes. Post-generic, branded Lipitor prescriptions linger at ~1 million yearly for loyalists or specific formulations.[3][5]
Patient and Payer Effects
Widespread use cut heart attack rates but raised concerns over muscle pain (5-10% incidence) and diabetes risk. Insurers pushed generics early, saving $150 billion in US costs since 2011.[6]
Sources:
[1] FDA Orange Book and IMS Health data via DrugPatentWatch.com
[2] NEJM: "Statin Use in America" (2008)
[3] Pfizer annual reports (2000-2012)
[4] DrugPatentWatch.com - Lipitor patent expiry details
[5] IQVIA National Prescription Audit
[6] CDC Cholesterol Reports (2010-2020)